FR22C1037I1 - GLYCOCONJUGATION METHODS AND COMPOSITIONS - Google Patents

GLYCOCONJUGATION METHODS AND COMPOSITIONS

Info

Publication number
FR22C1037I1
FR22C1037I1 FR22C1037C FR22C1037C FR22C1037I1 FR 22C1037 I1 FR22C1037 I1 FR 22C1037I1 FR 22C1037 C FR22C1037 C FR 22C1037C FR 22C1037 C FR22C1037 C FR 22C1037C FR 22C1037 I1 FR22C1037 I1 FR 22C1037I1
Authority
FR
France
Prior art keywords
glycoconjugation
compositions
methods
glycoconjugation methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1037C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of FR22C1037I1 publication Critical patent/FR22C1037I1/en
Application granted granted Critical
Publication of FR22C1037I2 publication Critical patent/FR22C1037I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FR22C1037C 2012-08-16 2022-07-28 GLYCOCONJUGATION METHODS AND COMPOSITIONS Active FR22C1037I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684043P 2012-08-16 2012-08-16
PCT/IB2013/056597 WO2014027302A1 (en) 2012-08-16 2013-08-12 Glycoconjugation processes and compositions

Publications (2)

Publication Number Publication Date
FR22C1037I1 true FR22C1037I1 (en) 2022-09-09
FR22C1037I2 FR22C1037I2 (en) 2023-05-26

Family

ID=49385307

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1037C Active FR22C1037I2 (en) 2012-08-16 2022-07-28 GLYCOCONJUGATION METHODS AND COMPOSITIONS

Country Status (30)

Country Link
US (6) US9517274B2 (en)
EP (2) EP2885007B1 (en)
JP (1) JP6291495B2 (en)
KR (1) KR101742406B1 (en)
CN (1) CN104661684B (en)
AR (1) AR092368A1 (en)
AU (1) AU2013303826B2 (en)
BR (1) BR112015003227B1 (en)
CA (1) CA2881420C (en)
DK (2) DK3421051T3 (en)
ES (2) ES2700824T3 (en)
FR (1) FR22C1037I2 (en)
HK (1) HK1210021A1 (en)
HU (3) HUE041381T2 (en)
IL (1) IL237066B (en)
IN (1) IN2015DN00694A (en)
MX (1) MX363511B (en)
MY (1) MY167579A (en)
NL (1) NL301188I2 (en)
NZ (1) NZ704490A (en)
PE (1) PE20150464A1 (en)
PH (1) PH12015500243B1 (en)
PL (2) PL3421051T3 (en)
PT (2) PT3421051T (en)
RU (2) RU2645071C2 (en)
SA (1) SA515360035B1 (en)
SG (1) SG11201500566XA (en)
SI (2) SI3421051T1 (en)
TW (1) TWI480049B (en)
WO (1) WO2014027302A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3421051T3 (en) 2012-08-16 2020-06-22 Pfizer Methods for glycoconjugation and compositions
PE20161095A1 (en) * 2014-01-21 2016-10-26 Pfizer IMMUNOGENIC COMPOSITIONS INCLUDING CONJUGATED CAPSULAR SACCHARID ANTIGENS AND THE USE OF THE SAME
KR102099741B1 (en) * 2014-01-21 2020-04-10 화이자 인코포레이티드 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096786B1 (en) * 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3104886B1 (en) * 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
PL3116887T3 (en) 2014-03-13 2021-09-06 Universität Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
PL3244917T3 (en) 2015-01-15 2023-07-17 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
IL297740A (en) * 2015-05-04 2022-12-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PE20180460A1 (en) * 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd METHODS TO IMPROVE THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND A MULTIVALENT VACCINE FORMULATION OBTAINED THROUGH THE SAME
RU2721128C2 (en) * 2015-07-21 2020-05-18 Пфайзер Инк. Immunogenic compositions containing conjugated antigens of the capsular saccharide, kits containing these compositions and use thereof
JP6849667B2 (en) 2015-09-16 2021-03-24 ウニヴェルズィテート バーゼル Carbohydrate ligand that binds to antibodies against glycosphingolipid sugar chain epitopes
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
AU2017306708B2 (en) 2016-08-05 2021-08-26 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2019001342A (en) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition.
FI3506935T3 (en) 2016-09-02 2024-04-17 Sanofi Pasteur Inc Neisseria meningitidis vaccine
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JP7186166B2 (en) 2016-12-30 2022-12-08 バックスサイト・インコーポレイテッド Polypeptide-antigen conjugates with unnatural amino acids
KR102459629B1 (en) 2017-01-20 2022-10-28 화이자 인코포레이티드 Immunogenic compositions for use in pneumococcal vaccines
JP7132954B2 (en) * 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー Multivalent conjugate vaccines comprising bivalent or multivalent conjugated polysaccharides providing improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR20200051003A (en) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2020007939A (en) 2018-02-05 2020-09-03 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition.
CU20200068A7 (en) * 2018-03-23 2021-04-07 Koranex Capital PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS
BR112020021296A2 (en) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. capsular polysaccharide of streptococcus pneumoniae and its immunogenic conjugate
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN111024832B (en) * 2019-10-29 2022-05-03 北京成大天和生物科技有限公司 Ion chromatography detection method for residual NaCNBH3 in polysaccharide conjugate vaccine
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Escherichia coli compositions and methods thereof
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
AU2021223184A1 (en) 2020-02-23 2022-08-18 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220088165A1 (en) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
PE20231934A1 (en) 2020-10-27 2023-12-01 Pfizer COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF
CN116744965A (en) 2020-11-04 2023-09-12 辉瑞大药厂 Immunogenic compositions for pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024522395A (en) 2021-05-28 2024-06-19 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578573A (en) 1897-03-09 Brake-actuating mechanism
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (en) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル Engine with oil removal device
DE69434079T2 (en) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid for the production of CRM protein and diphtheria toxin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1005564A4 (en) 1997-06-12 2003-04-23 Shinetsu Bio Inc Production of non-native bacterial exopolysaccharide in a recombinant bacterial host
BR9914160A (en) 1998-09-30 2001-06-26 American Cyanamid Co Antigenic composition, method for increasing the capacity of an antigenic composition that contains an antigen selected from a pathogenic bacterium, virus, fungus or parasite, haemophilus influenzae, helicobacter pylori, respiratory syncytial virus, rotavirus, and simple virus of the herpes to evoke the immune response of a vertebrate host, plasmid, host cell, method to produce an immunogenic mutant cholera holotoxin, and use of an effective auxiliary amount of a mutant cholera holotoxin
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DE19926475A1 (en) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Carrier-drug conjugates
SI21352A (en) * 2001-01-23 2004-06-30 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
DE60234695D1 (en) 2001-06-07 2010-01-21 Univ Colorado MUTANT TONS OF CHOLERA HOLOTOXIN AS ADJUVANS
JP2005508143A (en) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン Mutated form of cholera holotoxin as an adjuvant
CN1394867A (en) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 Medicinal oligose and its preparation method and medicine composition containing said oligose
WO2004031394A2 (en) * 2002-10-03 2004-04-15 Wyeth Holdings Corporation Process for preparing monoprotected diols from symmetric diols
WO2004080490A2 (en) 2003-03-07 2004-09-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP2007532655A (en) * 2004-04-14 2007-11-15 ワイス Process for preparing rapamycin 42-ester with dicarboxylic acid and FK-50632-ester with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
US7910753B2 (en) * 2004-09-10 2011-03-22 Anaspec Incorporated Cyanine dyes and their applications as luminescence quenching compounds
TWI445545B (en) 2005-04-08 2014-07-21 Wyeth Corp Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
EP3470080A1 (en) * 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
JP2009529050A (en) * 2006-03-07 2009-08-13 ワイス Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
DE102006026436A1 (en) * 2006-06-07 2007-12-13 Continental Aktiengesellschaft Method and measuring vehicle for determining objective tire properties on a road surface
AU2008265767B2 (en) * 2007-06-20 2014-11-13 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
RU2378015C2 (en) * 2008-04-02 2010-01-10 Равшан Иноятович Атауллаханов Conjugate for immunisation and vaccination and method for improving immunogenicity
SA114350400B1 (en) * 2009-06-22 2016-05-26 ويث ال ال سي Compositions and methods for preparing staphylococcus aureus 5 and 8 capsular polysaccharide conjugate immunogenic compositions
JP5837486B2 (en) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Compounds targeting cation-independent mannose 6-phosphate receptors
WO2011066291A2 (en) * 2009-11-24 2011-06-03 Talecris Biotherapeutics, Inc. Lyophilization methods, compositions, and kits
AR084158A1 (en) * 2010-12-10 2013-04-24 Merck Sharp & Dohme FORMULATIONS THAT MITIGATE THE AGGREGATION INDUCED BY AGMATION OF IMMUNOGENIC COMPOSITIONS
KR102226702B1 (en) * 2011-09-07 2021-03-11 프로린크스 엘엘시 Hydrogels with biodegradable crosslinking
DK3421051T3 (en) * 2012-08-16 2020-06-22 Pfizer Methods for glycoconjugation and compositions
PE20161095A1 (en) 2014-01-21 2016-10-26 Pfizer IMMUNOGENIC COMPOSITIONS INCLUDING CONJUGATED CAPSULAR SACCHARID ANTIGENS AND THE USE OF THE SAME
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates

Also Published As

Publication number Publication date
US10583187B2 (en) 2020-03-10
IN2015DN00694A (en) 2015-06-26
DK2885007T3 (en) 2018-12-03
US20230355735A1 (en) 2023-11-09
MY167579A (en) 2018-09-20
RU2016136630A (en) 2018-12-11
ES2700824T3 (en) 2019-02-19
NL301188I2 (en) 2024-05-15
AU2013303826A1 (en) 2015-02-12
US20180221467A1 (en) 2018-08-09
HUE049531T2 (en) 2020-10-28
MX2015001992A (en) 2015-10-05
PH12015500243A1 (en) 2015-03-30
SG11201500566XA (en) 2015-04-29
AR092368A1 (en) 2015-04-15
PL2885007T3 (en) 2019-02-28
SI3421051T1 (en) 2020-08-31
KR101742406B1 (en) 2017-05-31
SA515360035B1 (en) 2015-09-15
US20220096619A1 (en) 2022-03-31
HK1210021A1 (en) 2016-04-15
HUS2200034I1 (en) 2022-08-28
PH12015500243B1 (en) 2015-03-30
AU2013303826B2 (en) 2017-06-29
RU2016136630A3 (en) 2019-12-30
US20170224804A1 (en) 2017-08-10
RU2724840C2 (en) 2020-06-25
RU2645071C2 (en) 2018-02-15
PL3421051T3 (en) 2020-10-05
CA2881420C (en) 2016-11-15
FR22C1037I2 (en) 2023-05-26
TW201420115A (en) 2014-06-01
EP2885007A1 (en) 2015-06-24
US20150216996A1 (en) 2015-08-06
EP3421051A1 (en) 2019-01-02
WO2014027302A1 (en) 2014-02-20
BR112015003227A2 (en) 2017-07-04
DK3421051T3 (en) 2020-06-22
US9517274B2 (en) 2016-12-13
US11723965B2 (en) 2023-08-15
TWI480049B (en) 2015-04-11
EP2885007B1 (en) 2018-10-10
CN104661684B (en) 2018-03-20
KR20150041139A (en) 2015-04-15
ES2800479T3 (en) 2020-12-30
NZ704490A (en) 2017-07-28
PT2885007T (en) 2018-12-10
EP3421051B1 (en) 2020-05-13
JP6291495B2 (en) 2018-03-14
US20200246448A1 (en) 2020-08-06
IL237066B (en) 2019-03-31
PT3421051T (en) 2020-06-26
MX363511B (en) 2019-03-26
CA2881420A1 (en) 2014-02-20
JP2015524839A (en) 2015-08-27
US11110160B2 (en) 2021-09-07
PE20150464A1 (en) 2015-04-25
SI2885007T1 (en) 2018-12-31
BR112015003227B1 (en) 2020-10-27
CN104661684A (en) 2015-05-27
RU2015103017A (en) 2016-10-10
HUE041381T2 (en) 2019-05-28
US9950054B2 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
FR22C1037I2 (en) GLYCOCONJUGATION METHODS AND COMPOSITIONS
DK2935299T3 (en) Glycoconjugation procedure
DK2825087T3 (en) Otoscanner
DK2911506T3 (en) Operationally reducing compositions
DE112012006109A5 (en) Okklusionsschienenanordnung
DK3187586T3 (en) INDUCERABLE CO EXPRESSION SYSTEM
BR112014032798A2 (en) composition
BR112015001562A2 (en) biotins and compositions
DK2825157T3 (en) AMINOSYRELIPIDER
BR112014020547A2 (en) oily compositions and production methods
IT1402519B1 (en) IMPROVED MANNEQUIN
DK2849798T3 (en) OLIGONUCLEOTID-CHELAT COMPLEX-POLYPEPTIDE COMPOSITIONS AND PROCEDURES
DE112012006214T8 (en) Wulstringwickler
BR112014032712A2 (en) composition
DE112012005566T8 (en) Seltenerdnanoverbundmagnet
DK2811828T3 (en) ADJUVE COMPOSITIONS
DE102013212400A8 (en) ABDECKPLATTENSTÜTZBAUGRUPPE
FR2988587B1 (en) SELF-EMULSIFYING COMPOSITION
CO7071132A2 (en) Long acting compositions
DK2800573T3 (en) OTHAL MOLOGICAL COMPOSITION
DE112012007227A5 (en) Correspondence analysis method
DE202012013401U8 (en) Bioextruder
DE102012100780A8 (en) Zugmittelhebevorrichtung
ES1078331Y (en) DECORABLE REPOSTERY PIECE
ES1078574Y (en) MULTIPURPOSE EXHIBITOR